✨ Free AI Report
GRI BIO, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research GRI BIO, Inc.
Company Research

GRI BIO, Inc.: Business Overview, Financials & Competitive Analysis

GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The company focuses on modulating the activity of Natural Kil...

Analyst-debate audio for GRI BIO, Inc.

AskCyborg analysts argue the bull and bear cases for GRI BIO, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
4/ 10Mixed

Cyborg Score thesis

Early-stage NKT cell immunology platform with clinical programs in high-value indications, but challenged by capital intensity,...

Read the full analyst-debate transcript →
Industry Immunology Drugs
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 5, 2026
AI-Verified Research
30+ Page Report

Get the Latest GRI BIO, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

GRI BIO, Inc. Overview

Pro stress-test →

GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The company focuses on modulating the activity of Natural Killer T (NKT) cells, which it describes as key regulators early in the inflammatory cascade and a functional link between the innate and adaptive immune responses.

Strategic Profile

Pro stress-test →

Type I invariant NKT (iNKT) cells play a critical role in propagating injury, inflammation and fibrosis in inflammatory and fibrotic indications; GRI Bio's programs are built around inhibiting or activating specific NKT cell subsets to influence these disease processes. The company operates as a clinical-stage biotech with a proprietary NKT platform and multiple programs in development targeting high-unmet-need indications.

Competitive Landscape

Pro stress-test →

Comparable biotech companies include Palisade Bio Inc (PALI), Aditxt Inc (ADTX), Aptevo Therapeutics Inc (APVO), and Xenetic Biosciences Inc (XBIO). GRI Bio differentiates through its NKT cell targeting approach, which addresses disease pathology upstream of conventional small-molecule and biologic therapies. However, the company competes in a crowded immunology space against larger, better-capitalized biotechs with established pipelines.

Industry Context

GRI BIO, Inc. operates in Immunology Drugs.

Key facts

Founded: 2021 · Headquarters: La Jolla, CA · Employees: Unknown · Revenue: Pre-revenue · Market cap: $3.3M

What the analysts stress-tested

The top findings that survived the multi-agent debate for GRI BIO, Inc..

  • Lead program GRI-0621 is in Phase 2 development for Idiopathic Pulmonary Fibrosis (IPF), a disease with only two approved treatments and significant clinical need
  • GRI-0803, a Type 2 NKT agonist targeting Systemic Lupus Erythematosus (SLE), progressed to clinical development with Phase 1a/1b initiation planned
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2025Regained NASDAQ Minimum Bid Price Rule compliance after delisting concerns
  • February 2024Priced $5.5 million public offering at $1.10 per share with warrant issuance
  • +1 moreTrack every material event for GRI BIO, Inc. as it happens. Explore monitoring →
Get alerted when GRI BIO, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Regeneron Immunology PortfolioInflammatory and autoimmune disease treatments→Gilead ImmunologyInflammatory disease treatments and immunotherapies→Palisade Bio (PALI)Early-stage immunology biotech→Aptevo Therapeutics (APVO)Cell therapy and immunotherapy development→

Compare GRI BIO, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

GRI BIO, Inc. operates in Immunology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Immunology Drugs research →
NEW · MCP server

Ask your AI assistant about GRI BIO, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare GRI BIO, Inc. and its top competitor on Cyborg Score”
“What did GRI BIO, Inc. do this quarter?”
“Is GRI BIO, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does GRI BIO, Inc. do?+
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The company focuses on modulating the activity of Natural Kil...
What is GRI BIO, Inc.'s Cyborg Score?+
GRI BIO, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are GRI BIO, Inc.'s main competitors?+
Named competitors include Regeneron Immunology Portfolio, Gilead Immunology, Palisade Bio (PALI), Aptevo Therapeutics (APVO). The full competitive landscape is in the AskCyborg report.
How can I get the full GRI BIO, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the GRI BIO, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track GRI BIO, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.